Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO )

277.16 -29.20 (-9.53%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?
Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&P 500 and Nasdaq trading just above the flatline Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
From Bio-Rad Laboratories, Inc.
Via Business Wire
Earnings Scheduled For February 13, 2025
Via Benzinga
The Analyst Verdict: Bio-Rad Laboratories In The Eyes Of 4 Experts
Via Benzinga
Expert Ratings For Bio-Rad Laboratories
Via Benzinga
Triple-Witch Says, “Remember Me?”
Via Talk Markets
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
From Geneoscopy, Inc.
Via Business Wire
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
Via Benzinga
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Third-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
S&P 500 Shake-Up: New Entrants Driving Market Momentum
The quarterly rebalancing of the S&P 500 reflects market capitalization and performance shifts, highlighting growth and challenges in multiple sectors. 
Via MarketBeat
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Palantir Stock Will Join the S&P 500 in September. History Says It Could Soar Afterward.
History says Palantir stock could soar after its inclusion in the S&P 500. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Palantir Stock Soars After S&P 500 Inclusion, AI Deal With BP Fuels Additional Gains – What's Next?
Palantir (PLTR) stock surges due to inclusion in S&P 500 on Sept. 23 and new enterprise deal with BP. Technicals also show bullish trend. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Palantir, Dell Will Join The S&P 500. The AI Stocks Are Jumping.
Palantir, Dell Technologies and Erie Indemnity will join the S&P 500 on Sept. 23. All three stocks jumped late Friday. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Second-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
S&P 500 Ends First Half Shy Of All-Time Highs. Here Are The Leaders And Laggards — And 5 Stocks That Could Outperform In Next 6 Months
The market's resilient run has made traders cautious of a potential correction, but analysts remain optimistic about its trajectory. 
Via Benzinga
Topics Stocks
Exposures US Equities
OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Via AB Newswire
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For... 
Via TheNewswire.com
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
BIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024
BIO stock results show that Bio-Rad Laboratories beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.